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ABSTRACT:
RNA editing is crucial to the genetic diversity and structural complexity of
organisms. ADAR (adenosine deaminase acting on RNA) is an RNA editing enzyme that
creates a mutation of adenosine to inosine. The human ADAR2 (hADAR2) enzyme is
known to edit RNA; however, it contains minor sequence homology with the cytidine
deaminase enzymes, APOBEC and AID, which are known to edit both DNA and RNA (11
& 12). The ability of hADAR2 to edit DNA was tested through transformation into the
Saccharomyces cerevisiae yeast strain BY4741. DNA editing was tested by determining if
the transformed yeast became resistant to the antibiotic canavanine. Another editing
enzyme within the ADAR classification is adenosine deaminase that acts on tRNA
(ADAT). The structure of the ADAT1 from the organism, Candida albicans, will be
determined through x-ray crystallography. The plasmid expressing the caADAT enzyme
was purified from E. coli. The plasmid was then transformed into the Saccharomyces
cerevisiae strain BCY123. Expression of the ADAT gene was activated in yeast using the
GAL promoter system. caADAT protein is histone-tagged and was purified using a nickel
column. The crystals of the caADAT protein will be grown and diffracted to determine
the structure.

5

INTRODUCTION:
RNA editing refers to post-transcriptional changes to the RNA sequence. This
editing can appear in the form of point mutation, and it is essential to organism
function. RNA editing allows for changes to the RNA sequence without altering or
mutating the DNA. Through this process, one copy of DNA can create various strands of
RNA. If editing changes a codon within in an exon of a mRNA, this potentially leads to
the creation of multiple diverse proteins, allowing for complexity within the cell (11).
The discovery of RNA editing is fairly recent, occurring less than 40 years ago
with the discovery of adenosine deaminases that act on RNA (ADAR) (3).. This class of
enzymes creates point mutations, causing adenosine to be deaminated into inosine (Fig.
1). The adenosine is deaminated at the C6 position; this results in a carbonyl oxygen at
this position and results in another nucleotide, inosine (Fig. 1A). Inosine is often
recognized as guanosine due to its purine structure and C6 carbonyl oxygen (Fig. 1B).
This causes cytidine to base-pair to the inosine during replication, and effectively
creates an A to I, or more generally an A to G, mutation (Fig. 1) (8). The adenosine to
inosine mutation is a common post-transcriptional modification, and both the RNA and
protein structure can be affected (16). The A to G mutation can lead to a change in
structure of dsRNA through mismatches leading to bulges (17). If this mutation is in a
codon, it can lead to amino acid changes in the protein, which could cause an altered
protein shape or altered catalytic interactions. This could lead to a change in the protein
function. If the A to I mutation occurs in non-coding regions of the RNA, it can the
spliced out of the mRNA leaving the protein unaffected (19).
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Figure 1: Deaminase reaction mechanism (A) of ADAR enzyme creating A to I mutation
which effectively creates an A to G mutation in RNA (B) in the 34th and 37th position of
tRNAAla for S. cerevisiae (C) and C. albicans (D).

ADAR enzymes can catalyze the deamination of double-stranded RNA (dsRNA).
ADAR enzymes are found in metazoans only; there are over a million A-to-I sites in
humans occurring mainly in Alu sequences, which is a major short interspersed nuclear
element (SINE) (16). SINES are repeated non-coding sequences that give stability to the
RNA structure (2). This stability from Alu sequences makes A-to-I sites efficient ADAR
editing sites. There are three forms of ADAR in humans, hADAR1, hADAR2, and hADAR3.
hADAR1 is a longer protein than hADAR2 and hADAR3. It contains two Z-DNA binding
domains, three dsRNA binding motifs, and a catalytic domain. hADAR2 only contains
two dsRNA binding motifs and a catalytic domain. hADAR3 contains an R domain, which
is a ssRNA binding domain that is rich in arginine, along with two dsRNA binding motifs,
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and a catalytic domain. hADAR2 is the shortest protein (91.56 kDa) between hADAR1 &
hADAR3 (Fig. 2). hADAR3 is non-functional, in the sense that it can only bind to RNA, not
edit it (19).

Figure 2: Schematic Structure Comparison of ADAR enzymes.
The schematic structure depicts the relative length, Z-DNA binding domains (z) dsRNA
binding motifs (gray ovals), and catalytic domains (blue boxes) of each enzyme and the
species it is found in.

Truncated forms of recombinant hADAR2 can be created through overexpression
in Saccharomyces cerevisiae. This allows for truncations that still contain the catalytic
domain. This is possible due to the fact that Saccharomyces cerevisiae do not contain an
ADAR gene, making the overexpression system nontoxic (9). From these truncations,
specific domains of the ADAR protein, including the RNA binding motifs and the catalytic
domain, can be expressed and purified separately. These truncations retain their
activity.
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While the catalytic domain is highly conserved in different isoforms of ADARs, it
also has homology to cytidine deaminases (CDA), which are found in all organisms,
suggesting that ADARs evolved from CDAs (Fig. 3) (11). The cytidine deaminases with
conserved sequences include APOBEC-1, APOBEC-3G, and Activation Induced
Deaminase (AID). Cytidine deaminases are involved in both RNA and DNA editing
(9&13). AID, in particular, edits dsDNA, while cytidine deaminases within the APOBEC
family edit mRNA (15). Looking specifically at the structure of the catalytic domain, the
catalytic residues are conserved between CDAs and ADARs (Fig. 4). Both enzymes use a
coordinated zinc ion held in the coordination site by interactions with the following
residues, H394, C451, and C516. The nucleophilic water molecule is hydrogen bonded to
E396. CDA and hADAR2 have a high degree of structural aliment; however, ADARs, but
not CDAs require a molecule of inositol hexakisphosphate (IP6) (Fig. 4). IP6 is located in a
lysine and arginine rich cavity, along with additional water molecules (Fig. 4C). The
specific residues found in this cavity for hADAR2 are R400, R401, R532, K519, K629,
K662, K672, K690, W523, W687, Y658, Y668. These residues are conserved among ADAR
enzymes and ADAT1. This cavity is near the catalytic site (within 10 Å) and is indirectly in
coordination with the Zinc ions (8). The catalytic site is proposed to allow for the
nucleophilic attack of adenosine at the C6 position (8).
DNA editing can lead to permanent changes in the genome. While these changes
are typically associated with the negative effects of mutation, DNA editing can allow for
increased antibody diversity strengthening the adaptive immune response. Cytidine
deaminase enzymes, such as APOBEC3 or AID, are known to edit DNA and induce
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“programmed DNA damage” (4). Looking specifically at antibody diversity, the AID
enzyme mutates B cells through somatic hypermutation (SHM) and class switch
recombination (CSR). During SHM, the antigen binding region is mutated. During CSR,
the constant region of the antibody is switched with another. SHM & CSR increase the
diversity of the antibodies available, leading to antibodies with a higher affinity for
specific antigens. AID expression begins both of these processes and is highly regulated
(4 & 10). Along with antibodies, AID may mutate non-antibody genes (10). Mutation of
non-antibody genes could lead to permanent DNA damage including damage to genes
associated with cancer formation. AID has sequence homology to ADAR; therefore,
determining if ADAR can edit DNA could lead to future studies on antibody diversity and
other possible mutated non-antibody genes.
RNA editing contributes to genetic diversity and is essential for life, as ADAR
gene knockouts are lethal to mice (6 & 18). ADAR enzymes play a significant role in the
nervous system. ADAR enzymes affect the nervous system through A-to-I editing of a
CAG codon (glutamine to CIG (arginine) and introduction of an arginine from an A to I
mutation in the glutamate receptor (GluR). This arginine changes the calcium
permeability, making Ca2+ impermeable and decreasing neuronal conductivity. When
the gene encoding ADAR1 enzyme that edits this receptor is knocked out in mice, the
mice experience neurological changes including an array of symptoms. These mice were
found to have increased lethargy, epilepsy, and ALS. ADAR2 knockout throughout the
entire organism was found to be lethal post-natal in mice (13). The advancement of
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knowledge about ADAR enzymes could lead to future implications in the study of
neurological diseases, such as those listed above.
Along with neural implications from ADAR enzymes, psychological affects have
been correlated to the enzyme class as well. ADAR1 and ADAR2 are known to edit five
sites within the mammalian serotonin receptor (5-HT2c) pre-mRNA. The editing of this
receptor RNA decreases its affinity for serotonin. Increased levels of ADAR editing in this
receptor were found in suicide victims (1). Further experimentation on ADAR enzymes
could lead to a better understanding of this correlation and how to prevent increased
serotonin receptor editing. The first half of this thesis (project 1) focuses on further
ADAR experimentation through determining if human ADAR (hADAR1 and hADAR2) will
edit DNA.

Figure 3: Evolutionary pyramid showing the changes in bases edited, location of edit,
and requirement of IP6 from CDA to ADAR.
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Figure 4: Protein Structure (A), Catalytic active site comparison of CDA and hADAR2
(B), and IP6 binding site with interacting residues (C). Three views shown made using
Pymol software (1zy7 & 1mq0).
The catalytic active site of CDA (yellow) and hADAR2 (blue) is shown. Zn is shown as a
sphere. CDA catalytic active site is showing residues C65, E67, C99, and C102. hADAR2
catalytic active site is showing residues H394, E396, SC451, and C516. IP6 is shown in
lime green in coordination with hADAR2 with interacting residues (R400, R401, R532,
K519, K629, K662, K672, K690, W523, W687, Y658, Y668) shown in pink.

The second type of ADAR enzyme is adenosine deaminase acting on tRNA
(ADAT). ADATs create adenosine to inosine mutations in the 34th and 37th position of
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tRNA within the hair pin loop that contains the anticodon (8). As mentioned above,
ADAT contains the conserved catalytic domain; however, ADAT only contains this
domain and does not include any RNA binding motifs. The sequence homology is
stronger between ADAT and CDAs; therefore, it is suggested that ADATs are an
evolutionary intermediate between CDAs and ADARs (Fig. 3). ADAT enzymes are present
in both eukaryotes and prokaryotes; however, they are referred to as TadA in
prokaryotes (19). ADAT1 is found in all animals as well as fungi. One form of yeast,
Saccharomyces cerevisiae have three forms of ADAT: scADAT1, scADAT2, scADAT3 (10).
Looking specifically at these three forms of ADAT in yeast, scADAT1 deaminates the 37th
position of tRNAAla. scADAT2 and scADAT3 act as a heterodimer to deaminate the 34th
position of tRNA. The 34th position of tRNA is the wobble position within the anticodon
(8). Editing at position 34 increases the number of codons that can be recognized by the
modified tRNA and increases the efficiency of translation (14).
The crystal structure of scADAT2 and scADAT3 have been determined. scADAT2
and scADAT3 were found to be a heterodimer containing the conserved catalytic
domain along with other domains that are proposed to have structural implications (7).
From the crystallization of scADAT2 and scADAT3, an evolutionary relationship between
the eukaryote and prokaryote forms of ADAT was supported. The catalytic domain of
scADAT2 and scADAT3, once crystalized, were found to be similar to prokaryotic Tad A
(7). Looking beyond the 3D structure of this domain, the catalytic domain of these
eukaryotic enzymes was found to have the same four coordinating residues and zinc ion
as both the prokaryote form, TadA, and the previously mentioned hADAR2 (8).
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ADAT1 contains sequence homology with the other ADAR enzymes mentioned
above; ADAT2, ADAT3, Tad A, CDA, and other ADARs contain homologous catalytic
domain residues and zinc coordinating resides (7). Unlike ADAT2 and ADAT3, ADAT1
edits the 37th position as a monomer. Coordination to IP6 is essential for ADAT1 editing
(8). This is observed in hADAR2 but not in ADAT2 or ADAT3 (8). When comparing ADAT1
among yeast species, scADAT1 has sequence homology with ADAT1 from Candida
albicans (caADAT1); however, caADAT1 is shorter than scADAT1. From its truncated size,
caADAT1 is predicted to be a less dynamic protein making it easier to crystallize.
The physiological relevance of the 37th position where caADAT1 edits is not yet
known; however, it has been used as a target site for patients with inflammatory muscle
disease (5). It has also been proposed to enhance the fidelity of translation by the
ribosome through the altering of the tRNAAla structure. Determination of the structure
of caADAT could allow for further research including comparison of the 3D structures of
caADAT and scADAT and learning more about the biological relevance 37th nucleotide
position in tRNAAla. The second half (project 2) of this thesis focuses on determining the
structure of caADAT1 through purification and crystallization.
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MATERIALS & METHODS FOR PROJECT 1:
DETERMINING IF HUMAN ADAR EDITS DNA
DNA USED:
Multiple pJEL-ADAR plasmids were utilized in this experiment. Two functional
mammalian ADAR plasmids were used, human ADAR 1 (hA1) and human ADAR 2 (hA2).
Two truncated forms of hA2 were used including one form with the only the catalytic
domain (hA2CD) and one form with the catalytic domain and one dsRNA binding motif
(hA2RD). A mutated form of hA2 was used. The mutation was an alanine to glutamic
acid mutation at 396th position which is within the catalytic domain (hA2 E396A). The
ADAR plasmid from squid (sqA2) was analyzed as well. An empty vector control (EVC)
was used as the negative control. A cysteine deaminase, activation induced deaminase
(AID), was used as the positive control as it is known to edit both DNA and RNA.
E. COLI TRANSFORMATION:
The pJEL plasmids as listed above also include ampicillin (AMP) resistance for
selection in E. coli, and the URA3 gene for uracil production in ura-yeast mutants. The
pJEL-plasmids harboring various ADAR constructs were transformed into E. coli to
increase the amount of plasmid available. To 100 !" of competent E. coli cells, 1 !" of
plasmid was added. The cells were mixed and kept on ice for 30 minutes. The cells were
then heat shocked in a water bath at 42 °C for 40 seconds. The cells recovered on ice for
5 minutes. Then, the cells were added to 900 !" of Luria Broth (LB) and incubated for an
hour at 37 °C with shaking. The cells were centrifuged for 10 seconds. The pellet was
vortexed, and the cells were plated on LB-AMP plates and incubated at 37 °C.
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PLASMID PURIFICATION:
Transformed colonies from the LB-AMP plates were then inoculated. One colony
from each plate was added to 3 mL of LB media with a 1:100 dilution of AMP. This was
done for two trials of each of the ADAR and AID plasmids. The cells were incubated at
37 °C overnight with shaking. A mini prep was performed on the E. coli cultures to
purify the plasmids. The “High-Speed Plasmid Mini Kit Protocol” was followed. The
purified plasmid was stored at -20 °C.
RESTRICTION DIGEST & GEL ELECTROPHORESIS:
To ensure purification was successful and confirm the plasmid was correct, a
restriction digest was performed. The restrictive enzymes XhoI and BamHI were used.
The restriction enzymes were both used at a 3:100 dilution. Restrictive enzyme reaction
buffer #3 was used at a 10:100 dilution. To 3 !" of each plasmid DNA tested, 7 !" of the
restriction enzyme and buffer solution were added. The DNA was then gently mixed and
incubated at 37°C overnight.
Agarose gel electrophoresis was used to visualize the results of the restriction
digest. The gel was made using agarose powder and buffer solution for a 1% gel. Gel Red
was used at a 10000X concentration with the agarose gel solution. The gel was ran at
120 mV for 30 minutes. The fluorescent light microscope was used to visual the results
of the gel.
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YEAST TRANSFORMATION:
Yeast competent cells of the strain BY4741 were transformed using the purified
plasmid from each form of ADAR and AID. The transformation was done by
electroporation. To 40 !" of competent BY4741 cells, 3 !" of plasmid were added in a
2mm electroporation cuvette. The cells were electroporated using the pre-setting for S.
cerevisiae. After electroporation, 100 !" (0.65 M) of sorbitol were used to wash the cells
from the cuvette. 200 !" (20 mM) of the cells were plated on complete minimal -uracil
+dextrose (Cm-URA+Dex.) agar plates to select for cells harboring the plasmid.
YEAST GROWTH:
One colony of from the Cm-URA+Dex. plates for each plasmid and trial were
added to 3 milliliters of liquid Cm-URA+Dex. media and incubated at 30 °C overnight
with shaking to repress the promoter expressing the ADAR. This media was added to
1:100 Cm-URA+ glycerol/lactate liquid media and incubated at 30 °C overnight with
shaking to derepress the ADAR gene. To induce transcription, a 1:10 dilution of 20%
galactose was added to media following the 24 hour derepressed period. The cells were
incubated at 30 °C overnight with shaking. The cells were then plated on complete
minimal with canavanine antibiotic and lacking arginine production (Cm-ARG+Can).
These plates were then incubated at 30 °C.
DATA ANALYSIS:
If ADAR expression causes DNA mutations, growth of the canavanine resistant
cells would be expected. The negative control plasmids, which include the empty vector
and ADAR mutants, are expected to remain sensitive to canavanine. The colonies on the
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canavanine plates will be counted. The number of colonies on the plates with ADAR
expression will be compared to the number of colonies on the negative control plates.

MATERIALS & METHODS FOR PROJECT 2:
THE DETERMINATION OF THE CANDIDA ALBICANS ADAT STRUCTURE
THROUGH X-RAY CRYSTALLOGRAPHY
E. COLI TRANSFORMATION:
The pJEL plasmids that express the Candida albicans ADAT (caADAT) and the
Saccharomyces cerevisiae ADAT (scADAT) include ampicillin (AMP) resistance and the
URA3 gene that supports uracil production. The pJEL-caADAT and pJEL-scADAT plasmids
were transformed into E. coli to increase the amount of plasmid available. 3 !" of the
plasmid were added to 100 !" of competent E. coli cells. The cells were gently mixed
and kept on ice for 30 minutes. The cells were then heat shocked in a water bath at 42
°C for 45 seconds. The cells recovered on ice for 5 minutes. Then, the cells were added
to 1 mL of Luria Broth (LB) and incubated for an hour at 37 °C with shaking. The cells
were centrifuged for 10 seconds. The pellet was vortexed, and the cells were plated on
LB-AMP plates and incubated at 37 °C.
PLASMID PURIFICATION:
Transformed colonies from the LB-AMP plates were then inoculated. One colony
from each plate was added to 3 mL of LB media with a 1:100 dilution of AMP. This was
done for three trials of each ADAT gene. The cells were incubated at 37 °C overnight
with shaking. A mini prep was performed on the E. coli cultures to purify the plasmids.
The “High-Speed Plasmid Mini Kit Protocol” was followed. The purified plasmid was
stored at -20 °C.
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YEAST TRANSFORMATION:
Yeast component cells of the strain BCY123 were transformed using the purified
plasmid from the scADAT1 and caADAT1 trials. The transformation was done using the
electroporation. To 50 !" of competent BCY123 cells, 3 !" of plasmid were added in a
2mm electroporation cuvette. The cells were electroporated using the pre-setting for S.
cerevisiae. After electroporation, 100 !" (0.65 M) of sorbitol were used to wash the cells
from the cuvette and resuspended in 1 mL of sorbitol. 200 !" (20 mM) of the cells were
plated on agar plates of complete minimal media with 2% dextrose and lacking uracil
(Cm-URA+Dex.)
YEAST GROWTH:
One colony of from the Cm-URA+Dex. from each of the scADAT1 and caADAT1
plates were added to 3 mL of liquid Cm-URA+Dex. Media and incubated at 30 °$
overnight with shaking to repress the gal promoter of the ADAT gene. This media was
added to 1L of Cm-URA+ glycerol/lactate liquid media and incubated at 30 °$ overnight
with shaking to derepress the gal promoter controlling ADAT expression. 100 mL of 20%
galactose was added to media following the 24 hr derepressed period. Six hours after
adding galactose the activated cells were harvested through centrifugation and washed
with 1X PBS (9). Cell pellets were stored at -80 °$ until purification.
PROTEIN PURIFICATION:
The inoculated yeast cells were lysed using the homogenizer at 20,000 psi and
centrifuged at 25,000 g for 30 minutes at 4 °$. Multiple purification techniques were
used. The protein was purified using a nickel-NTA column to separate the protein from
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the solution. The ÄKTA machine was used for the nickel column using a 1x TGM (20 mM
Tris pH 8.0, 5% glycerol, and 1 mM 2-merceptoethanol) low imidazole (20mM) buffer
and a 1X TGM high imidazole (400mM) buffer each with an additional 400mM of NaCl.
The flowthrough, wash, and elution samples were ran on an SDS-PAGE gel and stained
with Coomassie blue. The elution sample was washed further and then dialyzed
overnight (9). When the ÄKTA machine was not used, cells were lysed, centrifuged at
25,000 x g for 30 minutes at 4 °$, then 5% polyethylene imine (PEI) was added to a final
concentration of 0.5%, in order to precipitate contaminating nucleic acids. The mixture
was then centrifuged at 25,000 g for 30 minutes at 4 °$. Ammonium sulfate was added
to 70% to precipitate the protein and remove any contaminating PEI. The ammonium
sulfate mixture was centrifuged at 25,000 g for 30 minutes at 4 °$. The pellet was
washed in 1X TGM, 250 mM NaCl, and 70% (NH4)2SO4. This was centrifuged at 25,000 g
for 30 minutes at 4 °$. The pellet was resuspended in the lysis buffer and nickel slurry
was added for metal affinity chromatography. Protein bound to the column was eluted
with 6 x 1 mL fractions using 1X TGM, 400 mM NaCl and supplemented with 400 mM
imidazole.
To ensure protein purification, both a sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel and western blot were run. Both 10% acrylamide gels
poured by me and 4-20% gradient acrylamide pre-poured gels were used. To pour the
10% acrylamide gel, the stacking gel was stacked on top of the separating gel. The
separating gel was made with 10% acrylamide, 1X SDS separating buffer (10% SDS and
1.5 M Tris-HCl (pH 8.8)), 0.1% ammonium persulfate (APS), and 100 !" of N,N,N’,N’-
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tetramethylethylene-diamine (Temed). The stacking gel was made with 10% acrylamide,
1X SDS stacking buffer (10% SDS and 0.5 M Tris-HCl (pH 6.8)), 0.1% APS, and 50 !" of
N,N,N’,N’-tetramethylethylene-diamine (Temed). 15 !" of the respective sample was
added to 5 !" 4X SDS-PAGE buffer. Bluestain was used as the molecular weight ladder.
Both pre-poured and hand-poured gels were ran at 200V for 40 minutes. The gel was
rocked in gel fixer for 5 minutes and then stained with Coomassie blue. The same SDS
gel procedure was used for the Western blot. The Whatman paper, western pads, and
membrane were soaked in 1X Towbin (25 mM Tris, 192 mM glycine, and 20% MeOH).
The transfer from the SDS-PAGE gel to the membrane was run at 40V for 30 minutes.
The membrane was then blocked in 5% non-fat dry milk in TTBS (20 mM Tris pH 7.5, 150
mM NaCl, 0.1% TWEEN20) for an hour. The primary antibody used Mouse Anti-His and it
was allowed to bind for an hour. The secondary antibody used was goat anti-mouse and
was allowed to bind for an hour. The membrane was washed between block, primary
antibody, and secondary antibody with TTBS. The membrane was developed with
alkaline phosphatase buffer and 1 NBT-BCIP pill. Once protein was confirmed, TEV
protease was added to the protein elutions and the solution was dialyzed in 1X TGM and
250 mM NaCl. After collecting the dialyzed solution, nickel slurry was added, and a
nickel column was completed.
X-RAY CRYSTALLIZATION:
The purified protein caADAT will be crystalized via vapor diffusion crystallization.
24 and 96 well crystallization trays containing broad screens of varying pH, salt, and
precipitation reagents will be employed to generate crystals of the caADAT1 protein.
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Once suitable crystals have been generated, they will be flash frozen in liquid nitrogen
and shipped to the Advanced Photon Source at Argonne National Laboratory for X-ray
diffraction. As part of a collaboration with the Eli Lilly Collaborative Access Team, an Eli
Lilly team member will collect the diffraction data and transmit it to Butler University,
where the data will be processed, and the protein model will be built.

RESULTS AND DISSCUSSION FOR PROJECT 1:
E. COLI TRANSORMATION AND RESTRICTION DIGEST TO CONFIRM ADAR PLASMIDS:
Following the transformation and mini prep of all seven ADAR constructs used a
restriction digest was run to confirm the plasmids were properly isolated. The seven
plasmids used to express human ADARs (hADAR) were hADAR1, hADAR2, hADAR2E396A (ADAR2 harboring an inactivating mutation), hADAR2-‘RD’ (containing one
dsRNA binding motif and the catalytic domain), hADAR2-CD (ADAR2 catalytic domain
only), and an empty vector control (EVC). A construct expressing Loligo opalescens
(squid) ADAR2 was also tested but abandoned early in the study. Using ApE
software, the known band sizes for each plasmid were compared to the picture
below (Fig. 5). Human ADAR1 was expected to have two bands (8823 & 2862); the
first of the hA1 replicates did not show this and was removed from the study. The
second replicate matched the expected sizing of hA1 and was used for further
testing. Human ADAR2 was expected to have four bands (8821, 1659, 481, & 38).
Both replicate lanes of hA2 matched the expected sizes and were retained for
further use. Human ADAR2 with a the E396A mutation was expected to match the
expected bands of hA2. This expectation was met. RD mutation of hADAR2 appeared
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to be accurate as all four (8821, 972, 481, & 38) expected bands were present. CD
mutation of hADAR2 was confirmed as all four (8821, 768, 481, & 38) expected
bands were seen; however, the first of the CD replicates was much lighter than the
second. Both of the squid ADAR2 plasmid replicates did not match the expected
bands (8823, 1132, 695, 478, & 152). The empty vector control plasmid, a pJEL
plasmid lacking ADAR insert, was used as a negative control and was expected to
only have one band, which was observed. Overall, most of the positive controls
matched their expected results, with the exception of the first hA1 replicate and
both sqA2 replicates, which were removed from the study. This confirmed the
transformation and isolation of the plasmids that were retained.

5 kb
4 kb
3 kb
2 kb
1 kb
750 bp
500 bp
Figure 5: Restriction Digest of each pJEL-ADAR plasmid used with the enzymes XhoI
and BamHI. Each pJEL-ADAR plasmid used either experimental or control was ran in a
restriction digest on an agarose gel. Gel-Red fluorescence was used to visualize the
results. The molecular weight ladder (MWL) and the empty vector control (EVC) were
run in the first and last lane. hADAR1 (hA1), hADAR2 (hA2), hADAR2 with E396A
(E396A). hADAR2-RD (RD), hADAR2-CD (CD), and sqADAR2 (sq) were run in duplicate.

YEAST TRANSFORMATION:
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To confirm yeast transformation, the electroporated cells were plated on CmURA+Dex. to select transformants. One colony was selected from these plates and were
inoculated into Cm-URA+Dex. liquid media, depressed with glycerol and lactic media,
then induced with galactose for different incubation periods to express the ADAR
proteins. The cells were then plated on Cm-ARG+Can plates. Cm-ARG+Can plates were
used to select for mutations in the Arginine transporter gene. The BY4741 strain can
produce arginine rather than needing to take it up from the environment. By using
arginine drop out plates, it ensures growth is only from the BY4741 strain that has been
mutated to prevent arginine and canavanine uptake from the media. The cytidine
deaminase AID is known to be canavanine resistant as it deaminates DNA and was used
as a positive control. The inclusion of the antibiotic canavanine ensures that only
colonies with the transformed plasmid can grow, if the gene for the transporter was
mutated preventing Canavanine uptake by the cell. Mutations can occur that would lead
to canavanine resistance; however, cells with ADAR edited DNA will be canavanine
resistant immediately and are expected to grow more colonies faster than cells that are
incurring random mutations. Yeast cells expressing the cytidine deaminase AID were
used as a positive control as they can become canavanine resistant as AID deaminates
DNA encoding an Arginine transporter. The first transformation resulted in no growth
on the Cm-ARG+Can plates for either hA2 or EVC. Table 1 shows the results of the
second transformation of hA2. hA2 had a much lower mutation frequency than the
negative control, which is the opposite of what is expected. At this point, I had
considered the possibility that hA2 and the EVC plasmids were accidentally switched. To
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determine if they had been switched, this experiment was repeated with the inclusion
of hA1 and AID. AID was used as a positive control as it is known to edit DNA. Tables 2,
3, and 4 show the results of the second transformation varying only in incubation
periods. The mutation frequency was determined and is summarized in Table 5. The
mutation frequency was higher for the negative control (EVC) for 1- and 6-hour
incubation periods. For the 24-hour incubation period, hA1 had the highest mutation
frequency; however, the mutation frequency was similar for the positive control,
negative control, and hA1. While the positive control, AID, was expected to have the
highest mutation frequency, it would need to be significantly higher than the negative
control. Overall, the negative control was expected to have the lowest mutation
frequency.

Table 1: Growth of hA2 and EVC on Cm-ARG+Can and YPD after 24 hr
Colony Forming Units (c.f.u.) Per Plate Type
Mutation
Vector
YPD Plate
Cm-ARG+Can
Frequency
hA2
1.05 × 10+
25
2.381 × 10/0
EVC
4.275 × 10+
4400
1.029 × 10/4
Growth on both YPD and Cm-ARG+Can plates was determined by counting the colony
forming units per plate and multiplying by the dilution used. The mutation frequency
was found by dividing the growth on the Cm-ARG+Can plates by the growth on the YPD
plates. Human ADAR2 (hA2) had less growth than the empty vector control (EVC).

Table 2: Growth of hAID, hA1, hA2, and EVC on Cm-ARG+Can and YPD after 1 hr
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Colony Forming Units (c.f.u.) Per Plate Type
Mutation
Vector
YPD Plate
Cm-ARG+Can
Frequency
0
hAID
6.75 × 10
250
3.700 × 10/6
325
hA1
2.50 × 100
1.300 × 10/4
125
1.850 × 10/6
hA2
6.75 × 100
925
EVC
4.75 × 100
1.950 × 10/4
Human Activation-Induced Cytidine Deaminase (hAID), Human ADAR1 (hA1), Human
ADAR2, and empty vector control (EVC) were grown on YPD and Cm-ARG+Can plates.
Growth on both YPD and Cm-ARG+Can plates was determined by counting the colony
forming units per plate and multiplying by the dilution used after 1 hr. The mutation
frequency was found by dividing the growth on the Cm-ARG+Can plates by the growth
on the YPD plates.
Table 3: Growth of hAID, hA1, hA2, and EVC on Cm-ARG+Can and YPD after 6 hr
Colony Forming Units (c.f.u.) Per Plate Type
Mutation
Vector
YPD Plate
Cm-ARG+Can
Frequency
hAID
1.375 × 10+
1225
8.910 × 10/6
950
7.600 × 10/6
hA1
1.250 × 10+
500
6.250 × 10/6
hA2
8.000 × 100
1800
EVC
1.600 × 10+
1.130 × 10/4
Human Activation-Induced Cytidine Deaminase (hAID), Human ADAR1 (hA1), Human
ADAR2, and empty vector control (EVC) were grown on YPD and Cm-ARG+Can plates.
Growth on both YPD and Cm-ARG+Can plates was determined by counting the colony
forming units per plate and multiplying by the dilution used after 6 hr. The mutation
frequency was found by dividing the growth on the Cm-ARG+Can plates by the growth
on the YPD plates.

Table 4: Growth of hAID, hA1, hA2, and EVC on Cm-ARG+Can and YPD after 24 hr
Colony Forming Units (c.f.u.) Per Plate Type
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Mutation
Vector
YPD Plate
Cm-ARG+Can
Frequency
hAID
1.825 × 10+
2550
1.400 × 10/4
4200
hA1
2.525 × 10+
1.660 × 10/4
825
8.460 × 10/6
hA2
9.75 × 100
2750
EVC
2.025 × 10+
1.360 × 10/4
Human Activation-Induced Cytidine Deaminase (hAID), Human ADAR1 (hA1), Human
ADAR2, and empty vector control (EVC) were grown on YPD and Cm-ARG+Can plates.
Growth on both YPD and Cm-ARG+Can plates was determined by counting the colony
forming units per plate and multiplying by the dilution used after 24 hr. The mutation
frequency was found by dividing the growth on the Cm-ARG+Can plates by the growth
on the YPD plates.
Table 5: Mutation Frequency for varying incubation times and vectors
Mutation Frequency
Time (hours)
1
6
24
Vector
hAID
3.70 x 10-7
8.91 x 10-7 1.40 x 10-6
hA1
1.30 x 10-6
7.60 x 10-7 1.66 x 10-6
hA2
1.85 x 10-7
6.25 x 10-7 8.46 x 10-7
EVC
1.95 x 10-6
1.13 x 10-6 1.36 x 10-6
Combined mutation frequencies from the above tables for Human Activation-Induced
Cytidine Deaminase (hAID), Human ADAR1 (hA1), Human ADAR2, and empty vector
control (EVC) over 1 hour, 6 hours, and 24 hours of incubation periods.

RESTRICTION DIGEST ON AID
Due to the negative control having a higher mutation frequency for both 1 hour and
6-hour incubation periods than the positive control, a second experiment was designed
to confirm the identity of the AID sample used. Two separate restriction digests were
ran on AID. One digest was ran with BambHI and XhoI. The second trial was ran using
the restriction enzymes BsrGI and XhoI.
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Figure 6: Restriction Digest of hAID using a variation of restrictive enzymes.
hAID plasmid was ran in a restriction digest on an agarose gel. The molecular weight
ladder (MWL) was ran in lane 1. In lane 2, hAID with enzymes BamHI and XhoI (B/X) was
ran. In lane 3, hAID with enzymes BsrGI and XhoI (BSR/X) was ran. Gel-Red fluorescence
was used to visualize the results.

Due to the unexpected performance of both the positive and negative controls
in multiple experiments, this project was terminated. The project was unsuccessful
possibly due to specifics of the yeast strain used or an error in the expression system.
This was further confirmed by the results of the AID restriction digest. The bands on the
digest are do not appear where the restriction enzymes are known to cut AID. The
failure of both the positive and negative controls led to the end of this project and the
beginning of project #2.
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RESULTS AND DISCUSSION FOR PROJECT #2
PURIFICATION #1
Successful transformation of the caADAT plasmid into the BCY123 strain of yeast
was confirmed due to the growth of electroporated caADAT BCY123 cells on CmURA+Dex. plates. Growth of the transformed cells ensure transformation as BCY123
alone would not be able to grow in media without uracil production assisted by the
URA3 gene encoded on the plasmid. This was confirmed as no colonies were observed
on the negative control plate which contained no transformed DNA. Upon confirmation
of successful transformation, the colonies were used to scale up expression of the ADAT
for purification.
7A

7B

Figure 7: Western Blot of cell lysate (1) and SDS gel following ÄKTA protein
purification
A Western Blot (7A) was used to determine if caADAT was activated and expressed in
the harvested yeast. The molecular weight marker used was Bluestain and was ran in
lane 1. BS2 was ran in lane 2 and was used as a positive control, as its size is known and
it contains a His-tag. The cell lysate (CL) was ran in replicate in lanes 3 and 4. The
membrane was developed in alkaline phosphatase with an NBT-BCIP assay. Protein
elutions from the ÄKTA machine were ran on a 10% SDS gel (7B) to determine if
purification was successful. The molecular weight ladder used was Bluestain in lane 1.
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Elutions 1, 3, 6, 9, 12, 15, 18, 21, and 24 (3 ml) were ran in lanes 2-10 respectfully. The
gel was stained with Coomassie.
The Western Blot confirmed that caADAT protein was present in the yeast cells
(Fig. 7A). This confirmation allowed for protein purification to continue. The harvested
cells were lysed, and the protein was purified using the ÄKTA machine. An SDS gel was
ran on the protein elutions from the Ni affinity chromatography through the ÄKTA
machine (Fig. 7B). Protein purification was unsuccessful as evidenced by the multiple
bands within the elution lanes. While it does appear that caADAT is present, it was not
pure.

PURIFICATION #2
The experiment was restarted with the plan of using a different purification
system. After successful transformation on Cm-URA+Dex. plates, the cells were
inoculated and harvested. The presence of caADAT protein was confirmed through
Western Blot (8A).
8A

8B
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8C

Figure 8: Western Blot of cell lysate (2), SDS gel of nickel column separation with PEI
prep, and SDS gel after dialysis and nickel column separation
A Western Blot (8A) was used to determine if caADAT was activated and expressed in
the harvested yeast. The molecular weight marker used was Bluestain and was ran in
lane 1. BS2 was ran in lane 2 and was used as a positive control, as its size is known. The
cell lysate was ran in replicate in lanes 3 and 4. The membrane was developed with
alkaline phosphatase and NBT-BCIP assay. A 10% SDS gel (8B) was ran using the ladder,
flow through, wash, and elutions 1-5 from the nickel column of caADAT following
protein prep. Bluestain ladder was used and ran in lane 1. The gel was stained with
Coomassie. A 10% SDS gel (8C) was ran of the ladder, flow through, wash, and elutions
1-5 of the nickel column following dialysis. Bluestain was used as the ladder and ran in
lane 1. Coomassie was used to stain the gel.
After confirming the presence of ADAT, the cells were lysed, prepped with PEI,
and purified through a nickel column. The flow through, wash, and elutions were ran on
an SDS gel to determine purification of caADAT (Fig. 8B). This SDS gel confirmed the
presence of caADAT in elutions 2-5. The size of the elution band confirmed the
purification of caADAT. Elution 1 was discarded and elutions 2-5 were pooled and
dialyzed with TEV protease.
Following dialysis, a nickel column was ran to remove the TEV protease with the
Histidine tag from the caADAT protein. The caADAT protein was suspected to be in the
flow through with the TEV protease and Histidine tag to be in the elution. After dialysis
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and the nickel column, the SDS gel did not show a band large enough to be caADAT (Fig.
8C). In order to determine why this was happening, the experiment was repeated,
starting from growing and harvesting new cells.
After harvesting the cell pellet, a western blot of the cell lysate was ran to
determine that caADAT was expressed. The bands in the cell lysate lane were smaller
than predicted; however, the bands were not very clear. The decision was made to
continue working with the pellet under the assumption that the protein was expressed.
A full lysis was done, followed by a nickel column to elute the caADAT protein. The
protein was dialyzed, and a second nickel column was ran to elute the TEV protease and
histidine tag with the expectation of caADAT in the flow through. Following the second
nickel column, an SDS gel was ran to confirm caADAT in the flow through. The
purification was unsuccessful again, with similar results to the previous purification
experiment: no bands in the flow through or wash and a faint band in the elution lanes
that is around the size of the TEV protease. A possible solution of using a detergent was
decided on. This would prevent unspecific binding to the nickel column. The experiment
was repeated from growth and harvest of the cell pellet; this allowed for the lysis and
purification to be repeated with 0.1% Triton detergent.

PURIFICATION #3
New cell cultures were grown up and harvested. To ensure caADAT protein
expression, a western blot was ran of the cell lysate (Fig. 9A). The bands looked slightly
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small for caADAT; however, the lanes did not appear to run exactly even, which could
account for the size discrepancy. The pellet was furthered used for lysis and purification.
9B

9A

9C

Figure 9: Western Blot of cell lysate (4), SDS gel following lysis, PEI prep, and nickel
column separation, and agarose gel of protein elutions from lysis and nickel column
separation with detergent addition.
A western blot (9A) of the Bluestain ladder, cell lysate (CL) in triplicate, and TM0077
protein was ran. The molecular weight marker used was Bluestain and was ran in lane 1.
The cell lysate was ran in triplicate in lanes 2, 3, and 4. TM0077 was ran in lane 5 and
used as a positive control, as its size is known. The membrane was developed with
alkaline phosphatase and NBT-BCIP assay. A 10% SDS gel (9B) was ran of the Bluestain
ladder, flow through, wash, and elutions 1-6 after cell lysis, PEI prep, and nickel
separation. The gel was stained with Coomassie. A 1% agarose gel (9C) was ran of the
RNA ladder and elutions 1-6 from the previous nickel column separation. Gel-Red
fluorescence was used to visualize the results.
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Following cell lysis and PEI prep, a nickel separation column was performed and
an SDS gel of the flow through, wash, and elutions was ran (Fig. 9B). The bands are
slightly smaller than caADAT; however, the gel did not run evenly, evident by the curve
in the bottom dark blue band of excess SDS loading dye. This was considered a
successful purification before dialysis. In order to ensure that the protein was still intact
following dialysis, an agarose gel was used to confirm no RNA was present in the protein
elutions (Fig. 9C). From the agarose gel, it was concluded that, overall, there was no
contamination of the protein with RNA. In the case of RNA contamination, I expected to
see a band of fluorescence of RNA staining the lanes; however, this is not what was
observed. Lane 1 had a slight fluorescence towards the bottom of the gel. From this gel,
the decision was made not to use elution 1. The remaining elutions were deemed to
lack RNA contamination and were further purified.
With confirmation of no RNA contamination, the protein was pooled and
dialyzed. For this trial, two different TEV solutions were used. The TEV used in the
previous trial was used, along with a freshly made solution of TEV. A western blot was
ran to confirm dialysis and to compare the different versions of TEV; this blot also
included the cell lysate from another round of growing and harvesting cells (Fig. 10A
lanes 2, 3). From this western blot, it was confirmed that the newly transformed cells
were expressing caADAT. The band is right at 42 kDa where caADAT was expected to be.
It was the only histidine tagged protein in the prep, which confirms successful lysis prep
and the absence other histidine tagged proteins. The BS2 positive control (Fig. 10A lane
4, 58 kDa) had slight spreading within the lane, but otherwise it looked as expected. The
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caADAT protein elution was much smaller than anticipated (Fig. 10A lanes 5,6, & 7); this
led to the conclusion that the wrong sample may have been ran. The sample reflects the
inclusion of the TEV protease. In the caADAT protein elution after dialysis with the
previously used TEV proteases solution (Fig. 10A lane 6), the smaller band (~10 kDa) is
still present; however, no TEV is seen. In the caADAT protein elution after dialysis with
the newly made TEV protease solution (Fig. 10A lane 7), the smaller band (~10 kDa) is
still present, as well as the TEV which is the larger smear (~27 kDa) above the smaller
band. Two possibilities arose for the presence of this smaller band. The first possibility
was that caADAT has degraded somewhere in the protein prep, causing it to be much
smaller. This much smaller protein is being unaffected by the TEV as it still has its
histidine tag; this could be due to a lower concentration of TEV protease in comparison
to caADAT. This caADAT fragment occurs with or without the TEV protease, both
previously made and newly made. It can be concluded that the histidine is still attached
to the caADAT fragment. The second possibility was the band is another histidine tagged
protein that is also unaffected by the TEV protease. Beyond the smaller band, the
western blot confirms that the newly made TEV protease should be used over the
previously made TEV protease. This is due to only the newly made TEV showing a band
at the expected size of 27 kDa.
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10B

10A

10C

Figure 10: Western Blot of cell lysate (5), positive BS2 control, and TEV trials, SDS gel
of the protein elutions before and after dialysis, SDS gel following lysis, dialysis, and
nickel column separation
A western blot (10A) of the cell lysate, BS2 positive control and caADAT protein elution
dialysis comparison. The molecular weight marker used was Bluestain in lane 1. The cell
lysate was ran in replicate in lanes 2 and 3. BS2 was ran in lane 4 and was used as a
positive control, as it’s size (54 kDa) is known. caADAT protein elution before dialysis
was ran in lane 5 (This elution was thought to not include TEV; however, after these
results the mix up as been confirmed, and this lane is confirmed to contain caADAT and
TEV before dialysis). caADAT protein after dialysis with the previously used solution of
TEV was ran in lane 6. caADAT protein after dialysis with the newly made solution of TEV
was ran in lane 7. The membrane was developed with alkaline phosphatase and NBTBCIP assay. A 10% SDS gel (10B) was ran to identify the smaller bands and
inconsistencies in the last western blot. The molecular weight marker used was
Bluestain, which was ran in lane 1. TM0077 (35 kDa) was ran in lane 2 and was used as
the positive control, as its size is known. Lane 3 was TEV protease (27 kDa) only. caADAT
pooled protein before dialysis was ran in lane 4. caADAT protein after dialysis with
previously made TEV was ran in lane 5. caADAT protein after dialysis with newly made
TEV was ran in lane 6. The cell lysate from that week’s cell growth and harvest was ran
in lane 7. The gel was stained with Coomassie. A 10% SDS gel (10C) was ran on the
protein elutions following dialysis with the newly made TEV. Bluestain was used as the
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molecular weight marker and was ran in lane 1. Lane 2 was the pooled protein before
dialysis with TEV. After dialysis, a nickel column was performed. The flow through was
ran in lane 3. The wash was ran in lane 4. The five elutions were ran in lanes 5-10. The
gel was stained with Coomassie.
To further test these possibilities a SDS gel was ran of the previously ran samples
(Fig. 10B). This gel confirmed that TEV had been added to the sample before dialysis
(lane 4) due to both the larger band expected to be caADAT around 42 kDa and the
smaller band expected to be TEV around 27 kDa. From this lane, two conclusions were
drawn. The first conclusion was that human error lead TEV to be in the pooled protein
concentration. The second conclusion was that caADAT was presence in the pooled
protein concentration, making this a successful purification before dialysis. Both caADAT
protein after dialysis with TEV variations also showed a band around the expected size
of caADAT (Fig. 10b lanes 5, 6). This was assumed to be a successful purification. From
this point, the decision was made to repeat this purification without the accidental
addition of TEV and using the newly made TEV only. This was done through another lysis
and purification prep.
A SDS gel was ran following dialysis and nickel separation (Fig. 10C). The flow
through is expected to have the caADAT protein in it; however, no band was seen. The
TEV is seen in bands in the elution lanes. The positive control, caADAT before dialysis
without TEV did not appear to have a band near the expected size of caADAT. From this
gel, it was concluded that the purification was unsuccessful.

37

PURIFCATION #4
The cell pellet that was used in the previous experiment was not freshly
harvested and was from an older cell plate. To ensure that the pellet was still viable and
caADAT was had not degraded, a western blot of the cell lysate from two identical
pellets to one that had just been previously used in the most recent lysis preparation
(Fig. 11A). The western blot confirmed the expression of caADAT in pellet #2; however,
pellet #1 did not appear to be expressing caADAT or the lysis of pellet was not complete.
For the next lysis, pellet #2 was used.
11A

11B

Figure 11: Western Blot of cell lysate from identical pellets of the previous sample and
SDS gel of Pellet #2 lysis and nickel column separation and Pellet #1 cell lysate.
A western blot (11A) of the cell lysate from two pellets ran in replicate was ran.
Bluestain was used as the molecular weight marker in lane 1. Pellet #1 was ran in
replicate in lanes 2 and 3. Pellet #2 was ran in replicate in lanes 4 and 5. TM0077 (35
kDa) was used as a positive control, as its size is known, in lane 6. The membrane was
developed with alkaline phosphatase and NBT-BCIP assay. A 10% SDS gel (11B) was ran
of the flow through, wash, and elution from the nickel separation column performed
following lysis. Bluestain was used as the molecular weight marker in lane 1. The flow
through was ran in lane 2. The wash was ran in lane 3. The six protein elutions were ran
in lanes 4-9. The cell lysate of pellet 1 was repeated and ran in lane 10. The gel was
stained with Coomassie.
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After the lysis and nickel column separation of pellet 2, the SDS gel did not yield
convincing results of a successful protein purification. caADAT was expected in the
elution lanes; however, the bands in the elution lane were too small to be a fully intact
caADAT protein (Fig. 11B). This gel confirms that new plates and new pellets needed to
be made and used in a timely manner to ensure no degradation occurs.
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CONCLUSION AND FUTURE DIRECTIONS:
After many failed protein purification attempts, caADAT appeared to be
degrading faster than it could be purified. The smaller than expected size of the caADAT
band in multiple gels could be due to the degradation of caADAT. This can be concluded
due to the constant size reduction that was seen throughout the multiple trials
performed. This could be remedied in future directions through the use of sequencing,
specifically protein sequencing before dialysis of the smaller than expected caADAT
protein elutions. This would confirm the presence of a truncated caADAT protein. Once
it is confirmed that caADAT is being truncated, protease inhibitors could be included in
the cell lysis and purification process to prevent truncation. Beyond the smaller than
expected size of caADAT, I was, overall, unable to successfully purify the protein
following dialysis. This could lead to future directions in dialysis trials, including
variations in dialysis timing, dialysis solution, or proteases used.
The immediate future directions of this project will include trials discussed above
to allow for successful purification. Following a successful purification of the protein, the
protein can be sent off for x-ray crystallography. This will allow for the structure of
caADAT to be determine, as outlined in the methods section above.
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